Becton, Dickinson & Stock News

FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: Citi's 2025 Unplugged Medtech and Life Sciences Access Day February 27, 2025 8:45 a.m.

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.

Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript

Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.

Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation  "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health care Biosciences and Diagnostic Solutions to realize its full ma...

Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectively BD completes $750 million share repurchase to date in FY25 Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing transla...

Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the medical technology company to sell its life sciences unit, the Financial Times reported on Monday.

FRANKLIN LAKES, N.J. , Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025 to holders of record on March 10, 2025.